Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial.

Welberry Smith MP, Cherukuri A, Newstead CG, Lewington AJ, Ahmad N, Menon K, Pollard SG, Prasad P, Tibble S, Giddings E, Baker RJ.

Transplantation. 2013 Dec 27;96(12):1082-8. doi: 10.1097/TP.0b013e3182a64db9.

PMID:
24056618
2.

Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.

Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS.

Health Technol Assess. 2005 May;9(21):1-179, iii-iv. Review.

3.

Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.

Krämer BK, Klinger M, Vítko Š, Glyda M, Midtvedt K, Stefoni S, Citterio F, Pietruck F, Squifflet JP, Segoloni G, Krüger B, Sperschneider H, Banas B, Bäckman L, Weber M, Carmellini M, Perner F, Claesson K, Marcinkowski W, Ostrowski M, Senatorski G, Nordström J, Salmela K.

Transplantation. 2012 Sep 15;94(5):492-8.

4.

Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.

Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, Tueros L, Hanson L, Rosen A, Ruiz P, Miller J.

Transplantation. 2008 Jul 15;86(1):67-74. doi: 10.1097/TP.0b013e3181734b4a.

PMID:
18622280
5.

Cost-benefit of steroid avoidance in renal transplant patients: a prospective randomized study.

Gheith OA, Nematalla AH, Bakr MA, Refaie A, Shokeir AA, Ghoneim MA.

Scand J Urol Nephrol. 2010 Apr;44(3):175-82. doi: 10.3109/00365591003649219.

PMID:
20230185
6.

Steroid avoidance reduce the cost of morbidities after live-donor renal allotransplants: a prospective, randomized, controlled study.

Gheith OA, Nematalla AH, Bakr MA, Refaie A, Shokeir AA, Ghoneim MA.

Exp Clin Transplant. 2011 Apr;9(2):121-7.

7.

Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.

Thomusch O, Wiesener M, Opgenoorth M, Pascher A, Woitas RP, Witzke O, Jaenigen B, Rentsch M, Wolters H, Rath T, Cingöz T, Benck U, Banas B, Hugo C.

Lancet. 2016 Dec 17;388(10063):3006-3016. doi: 10.1016/S0140-6736(16)32187-0. Epub 2016 Nov 19.

8.

Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial.

Chan K, Taube D, Roufosse C, Cook T, Brookes P, Goodall D, Galliford J, Cairns T, Dorling A, Duncan N, Hakim N, Palmer A, Papalois V, Warrens AN, Willicombe M, McLean AG.

Transplantation. 2011 Oct 15;92(7):774-80. doi: 10.1097/TP.0b013e31822ca7ca.

PMID:
21836540
9.

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.

3C Study Collaborative Group, Haynes R, Harden P, Judge P, Blackwell L, Emberson J, Landray MJ, Baigent C, Friend PJ.

Lancet. 2014 Nov 8;384(9955):1684-90. doi: 10.1016/S0140-6736(14)61095-3. Epub 2014 Jul 28.

PMID:
25078310
10.

Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results.

Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP.

Am J Transplant. 2005 Oct;5(10):2539-48.

11.

Alemtuzumab induction in deceased donor kidney transplantation.

Huang E, Cho YW, Hayashi R, Bunnapradist S.

Transplantation. 2007 Oct 15;84(7):821-8.

PMID:
17984833
12.

Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study.

Vítko S, Klinger M, Salmela K, Wlodarczyk Z, Tydèn G, Senatorski G, Ostrowski M, Fauchald P, Kokot F, Stefoni S, Perner F, Claesson K, Castagneto M, Heemann U, Carmellini M, Squifflet JP, Weber M, Segoloni G, Bäckman L, Sperschneider H, Krämer BK.

Transplantation. 2005 Dec 27;80(12):1734-41.

PMID:
16378069
13.

An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation.

Cherukuri A, Salama AD, Carter C, Smalle N, McCurtin R, Hewitt EW, Hernandez-Fuentes M, Clark B, Baker RJ.

Am J Transplant. 2012 Apr;12(4):919-31. doi: 10.1111/j.1600-6143.2011.03891.x. Epub 2012 Mar 5.

14.

Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.

Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK.

Transplantation. 2007 Jun 15;83(11):1509-12.

PMID:
17565326
15.

Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.

Becker T, Foltys D, Bilbao I, D'Amico D, Colledan M, Bernardos A, Beckebaum S, Isoniemi H, Pirenne J, Jaray J; MARSILEA Study Group.

Transplantation. 2008 Dec 27;86(12):1689-94. doi: 10.1097/TP.0b013e31818fff64.

PMID:
19104406
16.

Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.

Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.

Transpl Immunol. 2008 Nov;20(1-2):32-42. doi: 10.1016/j.trim.2008.08.005. Epub 2008 Sep 4.

PMID:
18773960
17.

Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial.

Bösmüller C, Ollinger R, Sieb M, Weissenbacher A, Schneeberger S, Pratschke J, Margreiter R.

Ann Transplant. 2012 Dec 31;17(4):45-51.

PMID:
23274323
18.

A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.

Ciancio G, Burke GW, Gaynor JJ, Roth D, Kupin W, Rosen A, Cordovilla T, Tueros L, Herrada E, Miller J.

Clin Transplant. 2008 Mar-Apr;22(2):200-10. doi: 10.1111/j.1399-0012.2007.00774.x.

PMID:
18339140
19.

Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation.

Uemura T, Ramprasad V, Matsushima K, Shike H, Valania T, Kwon O, Ghahramani N, Shah R, Farooq U, Khan A, Kadry Z.

Transplantation. 2011 Sep 27;92(6):678-85. doi: 10.1097/TP.0b013e31822b58be.

20.

Belatacept for kidney transplant recipients.

Masson P, Henderson L, Chapman JR, Craig JC, Webster AC.

Cochrane Database Syst Rev. 2014 Nov 24;(11):CD010699. doi: 10.1002/14651858.CD010699.pub2. Review.

PMID:
25416857

Supplemental Content

Support Center